Accelerating Profitable Growth

In 2014, Tecan successfully concluded major development projects and a wave of new exciting platforms and products is hitting the market to support and expand our position as the market leader in laboratory automation. It is our goal to enable efficient workflows in laboratories around the world. Everywhere researchers, clinicians and eventually patients rely on dependable, safe and fast results to improve health and the quality of life. 

This is why we are proud that our solutions accelerate, automate and enhance the processes in state-of-the-art diagnostics and life sciences labs. 

Our core business rests on two pillars: Partnering Business and Life Sciences Business. In the latter, Tecan has become the go-to partner for automation and analytical needs in the world’s life science research labs and has just launched next generation platforms in both main product lines to further build the leading market position. 2014 marked the successful launch of the Fluent™ Laboratory Automation Solutions, bringing the next level of innovation to automated liquid handling. Fluent is setting new standards for simplicity, productivity and confidence. In Tecan’s detection business, the new Spark™ multimode reader microplate brings greater flexibility and increases productivity for life sciences labs. Research & Development has been and will continue to be a cornerstone of Tecan’s success. In our evolution towards a total solutions business, however, Tecan also looks at acquisitions as a catalyst to its core business. In addition to our organic growth drivers, we look for innovative businesses to provide a dedicated solution offering with more recurring revenues. The acquisition of IBL International in July 2014 presents an important step in support of this evolution. 

At the heart of Tecan’s approach to acquisitions is a thoughtful expansion of the addressable market by complementing the existing product offerings. We are active in identifying targets and currently have a healthy list of potential targets in review and cultivation stage. We take, however, a disciplined approach on valuation to make informed decisions that benefit our business in the long term. Key functions are involved early in the process to ensure a successful integration. Also we pay attention that acquisitions do not compete with typical instrumentation customers of our Partnering Business.  

«It is our goal to enable efficient workflows in laboratories around the world.»

In our Partnering Business, we are the partner of choice for automation systems in the in-vitro diagnostics industry. We are supporting our clinical diagnostics partners with their regional product launches of new instruments – developed and manufactured by Tecan – and the associated ramp up in our serial production. The latest of these – the ORTHO VISION™ Analyzer from Ortho-Clinical Diagnostics – is now offering enhanced safety for transfusion medicine laboratories in Europe, Japan and Australia. Among the new platforms launched by partners is also the Dako Omnis for Dako (an Agilent Technologies Company), a fully automated advanced staining platform for tissue-based cancer diagnostics. This forward-thinking platform sets new standards with regard to flexibility, ease of use, capacity, efficiency and traceability. We have a well-stocked pipeline of additional opportunities and leverage Tecan’s platforms, technologies and service footprint to expand market share. 

In the components business, part of our Partnering Business, it is our goal to defend and expand our leading position for liquid handling components. Various customers are launching new instruments ramping up series production, which allows us to further grow this business. 

Tecan – Automating the Future of Labs 

We will shape the future of automatedworkflows in life science and clinical diagnostics through passion for unrivaled quality and innovation.